Top Markets
#1 Black Phoenix Black Phoenix +21,552.90%
#2 Nesa Nesa +732.45%
#3 Kinesis Silver Kinesis Silver +54.95%
#4 BNB Attestation Service BNB Attestation Service +26.43%
#5 Biconomy Biconomy +23.83%
#6 QuantixAI QuantixAI +23.16%
#7 EXOD EXOD +22.78%
#8 Pons Pons +20.90%
#9 Cash Cat Cash Cat +17.84%
#10 Derive Derive +16.78%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

688266
Rang in Aktien #3838
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries,... Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration clinical trial stages, such as gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, ruxolitinib-intolerant and relapsed/refractory myelofibrosis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, severe alopecia areata, nonsegmental vitiligo, and myelofibrosis; and recombinant human thyroid-stimulating hormone for injection. In addition, the company is developing drug candidates in Phase I/II clinical trial stages consisting of donafenib tablets for liver cancer and anti-tumor immunotherapy; gecacitinib hydrochloride cream for mild to moderate alopecia areata and atopic dermatitis, and nonsegmental vitiligo; ZG19018 and ZG2001 tablets for KRAS G12C and KRAS mutation late-stage solid tumors; and ZG005, ZGGS18, ZGGS15, ZG0895, and ZG006 powders for injections for late-stage solid tumors. Further, it develops pre-clinical drug candidates, including ZG1905 for topical bleeding; and ZGGS001 and GS11 powders for injections for late-stage tumors. The company’s products are used in multiple therapeutic areas, such as tumors, bleeding and blood diseases, and immune inflammatory diseases. Suzhou Zelgen Biopharmaceuticals Co., Ltd. was founded in 2009 and is based in Kunshan, the People's Republic of China.
Aktienkurs
$17.35
Marktkapitalisierung
$4.59B
Veränderung (1 Tag)
0.59%
Veränderung (1 Jahr)
14.36%
Land
CN
Handel Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266)

Kategorie

Healthcare
Aktien-Split-Historie für Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266)
Die Aktie Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Symbol: 688266) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 26, 2026 statt.
Eine 688266-Aktie, die vor dem Aug 26, 2026 gekauft wurde, entspricht heute 0 688266-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH